Loading…
Biomea Fusion, Inc. is projected to rise to $1.20 by 2027, a +3% move from its current price of $1.17. BMEA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.14 | $1.17 | $1.20 | -0.02% |
| Aug 6 | $1.13 | $1.17 | $1.21 | -0.04% |
| Aug 7 | $1.12 | $1.17 | $1.22 | -0.06% |
| Aug 8 | $1.11 | $1.17 | $1.23 | -0.08% |
| Aug 9 | $1.10 | $1.17 | $1.24 | -0.10% |
| Aug 10 | $1.09 | $1.17 | $1.25 | -0.12% |
| Aug 11 | $1.09 | $1.17 | $1.25 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.09 | $1.17 | $1.25 | -0.14% |
| Week 2 | $1.06 | $1.17 | $1.29 | -0.28% |
| Week 3 | $1.03 | $1.17 | $1.32 | -0.41% |
| Week 4 | $1.01 | $1.16 | $1.34 | -0.55% |
| Week 5 | $0.9916 | $1.16 | $1.36 | -0.69% |
| Week 6 | $0.9754 | $1.16 | $1.38 | -0.82% |
| Week 7 | $0.9606 | $1.16 | $1.40 | -0.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biomea Fusion, Inc. is a clinical-stage healthcare company focused on the discovery and development of oral medicines to treat diabetes and obesity. Its work centers on advancing drug candidates for metabolic diseases with lead programs under COVALENT-111 and COVALENT-112, which involve icovamenib and have completed Phase II trials for Type 1 and Type 2 diabetes.
COVALENT-211 and COVALENT-212 are in Phase II clinical trials for icovamenib aimed at insulin-deficient type 2 diabetes and type 2 diabetes, respectively. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trials for obesity. Biomea Fusion was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc. (BMEA) currently trades at $1.17 and carries a market cap of $84.59M, with a rank of 4220 among listed companies. The stock sits in a market with a relatively small capitalization and a challenging near-term technical setup as indicated by recent price action and indicators.
The near-term forecast for 2026 shows an average price of $1.17, within a range of $1.09 to $1.48, and a neutral sentiment. The 30-day price range spans $0.9806 to $1.40, reflecting modest volatility in the near term.
From 2027 through 2029, the forecast envisions ongoing, but gradual, upside with 2027 average $1.20 (ROI 2.5), 2028 average $1.28 (ROI 9.2), and 2029 average $1.32 (ROI 13.2), all labeled as neutral sentiment. Beginning in 2030, the outlook shifts to bullish, with rising averages and higher ROIs through 2050, culminating in a 2050 average price of $5.54 (ROI 373.8).
A major floor 17.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 25.6% above — a clean break opens room to run.
A major ceiling 88.9% above — clearing it would confirm fresh momentum.
Key BMEA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMEA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.22 | Sell | $1.22 | Sell |
| MA 10 | $1.26 | Sell | $1.24 | Sell |
| MA 20 | $1.29 | Sell | $1.27 | Sell |
| MA 50 | $1.29 | Sell | $1.31 | Sell |
| MA 100 | $1.42 | Sell | $1.37 | Sell |
| MA 200 | $1.37 | Sell | $1.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.18 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -191.42 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -9.30 | Sell |
| Bollinger %B (20,2) | -0.05 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 17.91 | Buy |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 1.20 | Sell |
| ADX (14) | 12.02 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical picture remains bearish, with RSI at 40. The stock trades around a $1.17 price, near support at $1.17, while the SMA50 sits at $1.29 and the SMA200 at $1.37. The 30-day range spans from $0.9806 to $1.40, illustrating limited upside momentum in the immediate horizon.
Annualized volatility sits around 50%, signaling notable near-term price variability. This combination suggests caution in the near term, with potential for a bounce if price holds the $1.17 support or a break above the $1.47 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.09 | $1.17 | $1.47 | 0% | Neutral | |
| $0.9592 | $1.20 | $1.59 | +3% | Neutral | |
| $0.9911 | $1.28 | $1.75 | +9% | Neutral | |
| $1.01 | $1.32 | $1.87 | +13% | Neutral | |
| $1.17 | $1.57 | $2.27 | +34% | Bullish | |
| $1.29 | $1.76 | $2.60 | +50% | Bullish | |
| $1.34 | $1.87 | $2.81 | +60% | Bullish | |
| $1.34 | $1.89 | $2.90 | +62% | Bullish | |
| $1.25 | $1.80 | $2.79 | +53% | Bullish | |
| $1.39 | $2.02 | $3.19 | +73% | Bullish | |
| $1.76 | $2.73 | $4.58 | +133% | Bullish | |
| $3.19 | $5.55 | $10.17 | +374% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.09 | $1.17 | $1.44 | +0.00% |
| September 2026 | $1.00 | $1.19 | $1.44 | +1.50% |
| October 2026 | $0.9657 | $1.15 | $1.41 | -3.24% |
| November 2026 | $0.9688 | $1.16 | $1.44 | +0.87% |
| December 2026 | $0.9831 | $1.18 | $1.47 | +1.99% |
Click any year to see its month-by-month BMEA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BMEA is projected to trade between $1.09 and $1.47, averaging $1.17 — a potential gain of 0% from today's $1.17. Price action looks broadly range-bound.
Biomea Fusion, Inc.'s 2027 outlook centres on $1.20, within a $0.9592 to $1.59 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, BMEA could reach as high as $1.75, with a base case around $1.28 and support toward $0.9911 — roughly +9% from $1.17. Price action looks broadly range-bound.
Expect BMEA to range from $1.01 to $1.87 through 2029. The $1.32 average target implies a +13% move from current prices. That is up +4% on the projected 2028 average. A consolidation phase looks the most probable path here.
The BMEA price prediction for 2030 points to an average of $1.57 (low $1.17, high $2.27) — a potential gain of +34% on today's $1.17. Momentum favours further upside here.
In 2031, BMEA is projected to trade between $1.29 and $2.60, averaging $1.76 — a potential gain of +50% from today's $1.17. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Biomea Fusion, Inc.'s 2032 outlook centres on $1.87, within a $1.34 to $2.81 range. That is up +6% on the projected 2031 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2033, BMEA could reach as high as $2.90, with a base case around $1.89 and support toward $1.34 — roughly +62% from $1.17. Buyers look set to stay in control over this stretch.
Expect BMEA to range from $1.25 to $2.79 through 2034. The $1.80 average target implies a +53% move from current prices. That is -5% versus the projected 2033 average. Momentum favours further upside here.
The BMEA price prediction for 2035 points to an average of $2.02 (low $1.39, high $3.19) — a potential gain of +73% on today's $1.17. Buyers look set to stay in control over this stretch.
In 2040, BMEA is projected to trade between $1.76 and $4.58, averaging $2.73 — a potential gain of +133% from today's $1.17. That is up +35% on the projected 2035 average. Momentum favours further upside here.
Biomea Fusion, Inc.'s 2050 outlook centres on $5.55, within a $3.19 to $10.17 range. That is up +103% on the projected 2040 average. That marks a +374% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BMEA today (≈ 854.700855 BMEA) could be worth
$4,739.68
+$3,739.68 (+374%) by 2050 · US Dollar
Based on the average projected BMEA price of $5.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMEAwould be worth at today's price.
$1,000 invested in BMEA on Jul 31, 2025 (≈ 602.409651 BMEA) would be worth
$704.82
-$295.18 (-29.5%) today · 0.70× · US Dollar
Based on a BMEA entry price of $1.66 vs. today's $1.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.25 | $936 | -6.4% |
| 1 month ago | $1.36 | $860.29 | -14.0% |
| 3 months ago | $1.37 | $854.01 | -14.6% |
| 6 months ago | $1.1 | $1,063.64 | +6.4% |
| 1 year ago | $1.66 | $704.82 | -29.5% |
| All time (5.0y) ago | $12.81 | $91.33 | -90.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMEA forecast.
Our base-case forecast reaches $2.30 around 2040.
Implied market cap at $2.30: $166.29M
The multi-year forecast turns notably bullish from 2030 onward, with the average price rising to $1.57 and a 34 (ROI) in 2030. The trajectory continues higher in 2031 ($1.76 avg, ROI 50.7), 2032 ($1.87 avg, ROI 59.7), and 2033 ($1.89 avg, ROI 61.5), reflecting sustained upside.
By 2035, the average price is projected at $2.02 with ROI 72.9, and in 2040 the average price lifts to $2.73 with ROI 133.5. The long-run view extends to 2050, with an average price of $5.54 and ROI of 373.8, both labeled bullish. These figures imply substantial upside potential in the later years, though they are estimates and not guarantees.
Overall, the long-term outlook for Biomea Fusion shows a transition from neutral to bullish sentiment as the price pathway climbs, driven by higher forecast averages and accelerating ROI in the latter years. Investors should consider the uncertainty inherent in such long-range projections and weigh it against the sizable upside suggested by the 2030–2050 forecasts.
Tap a question to reveal the answer.
Avg price $1.57; max $2.27; min $1.17; ROI 34; sentiment BULLISH.
The long-term forecast shows bullish sentiment from 2030 onward with an avg price of $5.54 by 2050 and ROI 373.8, but these are estimates and not guarantees.
Yes. The 2030 max is $2.27, with higher maxes in later years (2035 max $3.19, 2040 max $4.58, 2050 max $10.17), indicating $2.00 is within the forecast in 2030 and beyond.
Bearish sentiment with RSI 40. The price is near support at $1.17, with SMA50 $1.29 and SMA200 $1.37. The 30-day range is $0.9806 to $1.40, and volatility is about 50%.
Current price $1.17; Market cap $84.59M; Rank 4220.
Biomea Fusion, Inc. Community Discussion
0Share your Biomea Fusion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.